Skip to main content

UMH PROPERTIES, INC. TO PARTICIPATE IN NAREIT’S REITWEEK: 2026 INVESTOR CONFERENCE

FREEHOLD, NJ, May 22, 2026 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), today announced that the Company will participate in Nareit’s REITweek: 2026 Investor Conference, to be held in New York City, at the New York Hilton Midtown. UMH’s senior management team is scheduled to present on Tuesday, June 2, 2026, at 10:15 a.m. Eastern Time. The presentation will be available live via webcast and accessible on the Company’s website, www.umh.reit, in the Upcoming Events section. The webcast replay will be available for 60 days after the presentation. Presentation materials will also be available on the Company’s website homepage. UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of...

Continue reading

Timbercreek Financial Declares May 2026 Dividend

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) — Timbercreek Financial Corp. (TSX: TF) (the “Company” or “Timbercreek Financial”) is pleased to announce that it has declared a monthly cash dividend of $0.0575 per common share (“Common Share”) of the Company to be paid on June 15, 2026 to holders of Common Shares of record on May 29, 2026. The Company also offers a Dividend Reinvestment Plan (the “Plan”), which is eligible to holders of Common Shares and provides a convenient means to purchase additional Common Shares by reinvesting cash dividends at a potential discount and without having to pay commissions, service charges or brokerage fees. Pursuant to the Plan and at the discretion of Timbercreek Capital Inc., (the “Manager”), Common Shares will be acquired in the open market at prevailing prices or issued from treasury at 98 percent...

Continue reading

Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million. The financing includes leading U.S. biotechnology institutional investors and mutual funds. Morgan Stanley acted as the lead book-running manager and BofA Securities acted as book-running manager for the offering. LifeSci Capital, Mizuho and Needham &...

Continue reading

Apogee Acquisition Corp Announces the Separate Trading of Its Class A Ordinary Shares, Warrants and Rights, Commencing on May 28, 2026

New York, NY, May 22, 2026 (GLOBE NEWSWIRE) — Apogee Acquisition Corp (Nasdaq: AACPU) (the “Company”) today announced that, commencing on May 28, 2026, holders of the units (the “Units”) sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares (the “Ordinary Shares”), warrants (the “Warrants”) and rights (the “Rights”) included in the Units. The Ordinary Shares, Warrants and Rights received from the separated Units will trade on the Nasdaq Global Market (“Nasdaq”) under the symbols “AACP,” “AACPW” and “AACPR,” respectively. Units that are not separated will continue to trade on Nasdaq under the symbol “AACPU”. Holders of Units will need to have their brokers contact Efficiency INC., the Company’s transfer agent, in order to separate the Units into Ordinary Shares, Warrants...

Continue reading

Empro Group Inc. Announces Receipt of Delinquency Notification from Nasdaq

Selangor, Malaysia, May 22, 2026 (GLOBE NEWSWIRE) — Empro Group Inc. (Nasdaq: EMPG) (“Empro Group” or the “Company”), a rising beauty and personal care brand headquartered in Malaysia, today announced that on May 19, 2026 it received a notice from The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company has not yet filed its annual report on Form 20-F for the fiscal year ended December 31, 2025. Under Nasdaq rules, the Company has 60 calendar days to submit a plan to regain compliance and, if such plan is accepted by Nasdaq, an exception of up to 180 calendar days from the original filing’s due date may be granted, or until November 11, 2026, to regain compliance. If the plan to regain compliance is not accepted, the Company will have the opportunity to appeal...

Continue reading

NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces that the underwriters of its previously announced global offering (the “Global Offering”) have fully exercised their option to purchase 33,805 additional new ordinary shares in the form of additional American Depositary Shares (the “Additional ADSs”) (the “Option”). Each Additional ADS represents one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company and the offering price of $38.98 per Additional ADS corresponds to a price of €33.60 per Ordinary Share (on the basis of an exchange rate...

Continue reading

ACP Holdings Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about May 28, 2026

Houston, TX, May 22, 2026 (GLOBE NEWSWIRE) — ACP Holdings Acquisition Corp. (Nasdaq: ACGCU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 21,461,600 units, which includes 1,461,600 units issued pursuant to the partial exercise by the underwriter of its overallotment option, completed on April 8, 2026 (the “Offering”), may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about May 28, 2026. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol “ACGCU”, and each of the Class A ordinary shares and warrants will separately trade on The Nasdaq Global Market under the symbols “ACGC” and “ACGCW,” respectively. No fractional warrants will be issued upon separation of the units and only whole...

Continue reading

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS’s Common Stock to Begin Trading on Post-Split Adjusted Basis on June 1, 2026 JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-8, effective at 4:05 p.m. ET on May 29, 2026. SCYNEXIS’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on June 1, 2026 under SCYNEXIS’s existing trading symbol “SCYX” with a new CUSIP number, 811292 309. The reverse stock split was approved by SCYNEXIS’s stockholders at SCYNEXIS’s Special Meeting held on May 19, 2026, with the final ratio subsequently determined...

Continue reading

Terra Innovatum Provides Update on Form 10-K and First Quarter 2026 Reporting Timeline

Company expects to file 2025 Form 10-K on or prior to June 15 First quarter 2026 Form 10-Q expected to follow promptly after annual filing NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (NASDAQ: NKLR) (“Terra” or the “Company”), a Nasdaq listed company, today disclosed receipt of a Nasdaq Listing Delinquency Letter and provided an update on the timing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. Terra Innovatum continues to work diligently to complete its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. As previously disclosed, the Company is taking the necessary time to ensure the filing is aligned with its post-combination reporting requirements and accurately reflects the...

Continue reading

Japan Smaller Capitalization Fund, Inc. Announces Commencement of Tender Offer and Re-Leveling of Level Distribution Plan

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) — In connection with Japan Smaller Capitalization Fund, Inc. (the “Fund”) (NYSE: JOF)’s previously announced conditional tender offer, the Fund today announced that its Board of Directors (the “Board”) has approved a tender offer (the “Tender Offer”) to purchase up to 10% of its issued and outstanding shares at a price per share equal to 98% of the net asset value (“NAV”) per share as of the pricing date. The Tender Offer is expected to commence on June 1, 2026, and expire at 5:00 p.m. on July 1, 2026 (the “Expiration Date”), with a pricing date of July 2, 2026, unless extended. If more shares are tendered than the maximum amount specified in the offer, the Fund intends to purchase shares from tendering shareholders on a pro rata basis, based on the number of shares tendered by each shareholder. The...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.